RXRA

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 28, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, IND, RXRA, Biotechnology, Drug discovery, Cancer, Retinoid X receptor alpha, Flare, Disease, Recurrence, Squamous cell carcinoma, Peroxisome proliferator-activated receptor gamma, Inflammation, Senior, HIV disease progression rates, Neurology, Neoplasm, Patient, Bladder cancer, FGFR3, RWD, Lists of diseases, Third Rock Ventures, Therapy, UC, Investigational New Drug, Knowledge, Incidence, Factor X, Pharmaceutical industry, PPARG, Biology

Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.

Key Points: 
  • Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.
  • This disease has high rates of recurrence and the five-year survival rate is approximately 5% in metastatic cases.
  • The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC patients.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Lists of diseases, RXRA, Disease, Therapy, Squamous cell carcinoma, IND, Factor X, Neoplasm, Biotechnology, Bladder cancer, Patient, Biology, Inflammation, Cancer, Drug discovery, Neurology, Incidence, Breast, Retinoid X receptor alpha, Prostate cancer, Recurrence, Third Rock Ventures, Gene silencing, Gene, Pharmaceutical industry, Medical imaging, PPARG, Flare, UC

Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.

Key Points: 
  • Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.
  • In preclinical models, FTX-6746 demonstrated a favorable therapeutic profile, suppressing PPARG target genes with durable tumor regression at well-tolerated doses.
  • Flare is poised to transition to a clinical-stage company early next year with our lead molecule in the PPARG program.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.